Mavys received her PhD in Pharmacy from the University of Granada, working on the design and synthesis of new HDAC inhibitors as anticancer drugs. Her background includes chemical synthesis, microencapsulation, biosensors, biomaterials, scale up and optimization of processes. Mavys joined DESTINA in March 2013, after several years of experience in biotech companies. She is responsible for the integration DESTINA’s technology onto several platforms.
